So the lack of patients with Covid19 and not being treated with pharmaceutical drugs, which means the control group is a problem for recruitment AND to show survival comparitively when treated by remestemcel-L
makes the ENTIRE portfolio of MSB not worth it?
do tell us more Kakala! You're a prince of understatement and rational thought....NOT.
Also you misrepresent me entirely, nothing new there. You're also one of the laziest posters in HC.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-371
-
- There are more pages in this discussion • 705 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |